Covid19
Conditions
Brief summary
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS-CoV-2 and no therapeutic agent to treat COVID-19. This clinical trial is designed to evaluate the potential of Brensocatib (INS1007) as a novel host directed therapy for the treatment of adult patients hospitalized with COVID-19. The investigators hypothesise that Brensocatib, by blocking damaging neutrophil proteases, will reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in patients with COVID-19, thereby resulting in improved clinical outcomes at day 15 and day 29, fewer days dependent on oxygen or mechanical ventilation, and shorter length of hospital stay. High rates of patients requiring mechanical ventilation and overwhelming intensive care unit capacity has been the major issue contributing to excess deaths in Italy and Spain during the pandemic and is likely to be a major issue in other countries such as the United Kingdom in the coming weeks. Treatments that could prevent the requirement for mechanical ventilation or shorten the duration of ICU stay by reducing the severity of ARDS are therefore the number 1 target for COVID19 therapy. The investigators recently conducted a large phase 2 study of Brensocatib in patients with bronchiectasis designed to test if treatment with Brensocatib could reduce infective exacerbations and reduce neutrophil elastase activity in the lung in bronchiectasis patients. The study met its primary endpoint of time to first exacerbation and key secondary endpoint of the frequency of exacerbations as well as showing marked reductions in neutrophil elastase concentrations in sputum. Participants will be randomised to receive Brensocatib or placebo 25mg orally once daily for 28 days.
Detailed description
BACKGROUND COVID-19 is a respiratory disease caused by a novel coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and causes substantial morbidity and mortality.This clinical trial is designed to evaluate the potential of Brensocatib as a novel host directed therapy for the treatment of adult patients hospitalised with COVID-19. The investigators hypothesise that Brensocatib, by blocking damaging neutrophil proteases, will reduce the incidence of acute lung injury and acute respiratory distress syndrome (ARDS) in patients with COVID-19, thereby resulting in improved clinical outcomes at day 15 and day 29, fewer days dependent on oxygen or mechanical ventilation, and shorter length of hospital stay. Coronavirus (CoVs) are positive-sense single stranded enveloped Ribonucleic acid (RNA) viruses, many of which are commonly found in humans and cause mild symptoms. Over the past two decades, emerging pathogenic CoVs capable of causing life-threatening disease in humans and animals have been identified, namely severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) and Middle Eastern respiratory syndrome coronavirus (MERS- CoV). In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) identified an outbreak of viral pneumonia cases of unknown cause.5 Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been abbreviated as SARS-COV-2 and has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. This novel coronavirus has been designated SARS-CoV-2, and the disease caused by this virus has been designated COVID-19. Initial infections were travel associated with individuals having contact with Wuhan or other affected areas but the disease has now spread to affect hundreds of thousands of patients worldwide with widespread community transmission across the globe. Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise. Global efforts to evaluate novel antivirals and therapeutic strategies to treat COVID-19 have intensified but to date dexamethasone is the only therapy shown to reduce mortality in COVID-19 while repurposed antiviral drugs did not show clinical benefits in the World Health Organisation SOLIDARITY trial. Mortality from COVID-19 has been estimated at between 0.5% and 3.4% of infected patients and occurs most frequently because of the development of ARDS. In contrast to some, particularly bacterial pneumonias, where patients present with acute respiratory failure and sepsis, the dynamics of COVID-19 infection demonstrate a slow deterioration in oxygenation with the development of bilateral infiltrates in a high proportion of patients, consistent with the development of ARDS. Patients subsequently require mechanical ventilation. Treatments that could prevent the requirement for mechanical ventilation or shorten the duration of intensive care unit stay by reducing the severity of ARDS are therefore the number 1 target for COVID-19 therapy. Neutrophils in ARDS Neutrophil influx into the extravascular compartments of the lungs is a defining characteristic of ARDS. During ARDS, circulating neutrophils become primed, resulting in reduce deformability and retention within the pulmonary capillary bed. They then migrate across the endothelium through the interstitium and epithelium into the airways themselves. As neutrophils migrate they are activated and release oxidants, proteases and neutrophil extracellular traps. All of these processes are important in killing bacterial pathogens but in ARDS these processes become prolonged and excessive leading to progressive lung damage. Neutrophil elastase and other neutrophil proteases such as proteinase-3 and cathepsin-G cause tissue injury resulting in increased epithelial and endothelial permeability which leads to the influx of protein-rich alveolar oedema. Mortality in ARDS correlates directly with the extent of neutrophilia in the lung. Both human clinical data and murine studies demonstrate a key role for neutrophils in ARDS. Neutrophil depletion in multiple models of ARDS including those induced by lipopolysaccharide, acid, ventilator lung injury, transfusion and other stimuli, reduces the severity of acute lung injury including endothelial-epithelial cell damage and capillary-alveolar permeability. Neutrophil proteases and particularly neutrophil elastase are believed to be central to the neutrophil induced lung damage. Neutrophil elastase is a serine protease contained within primary neutrophil granules which is released in response to neutrophil activation or neutrophil extracellular trap formation. It is involved in the pathogenesis of multiple inflammatory diseases and therapeutic development of neutrophil elastase inhibitors for use in ARDS has been ongoing for many years. Neutrophil elastase is markedly elevated in human ARDS samples and the inhibition of neutrophil elastase has been demonstrated to reduce epithelial injury in multiple animal models of lung injury across multiple stimuli including lipopolysaccharide (LPS), bleomycin, ventilation, sepsis and many others. Neutrophil elastase is critical to the development of neutrophil extracellular traps, which are highly damaging webs of DNA studded with proteases and other neutrophil derived toxins. Neutrophil extracellular traps (NET) formation and the failure to clear NETs have been strongly implicated in the development and poor outcomes from ARDS. Inhibition of neutrophil elastase reduces the formation of NETs. A challenge therapeutically has been how to inhibit neutrophil elastase since administration of competitive inhibitors either orally or through the inhaled route may not be sufficient to block elastase activity in the lung. RATIONALE Neutrophil elastase, proteinase-3 and cathepsin-G are activated during neutrophil maturation in the bone marrow through dipeptidyl peptidase 1 (DPP1; also known as cathepsin C), which removes the N-terminal dipeptide sequence of neutrophil serine proteases allowing active enzymes to be packaged into granules prior to release of neutrophils into the circulation. Brensocatib (INS1007, formerly AZD7986) is an orally delivered selective, competitive, and reversible inhibitor of DPP1. Brensocatib has been shown to inhibit neutrophil serine protease activity in blood in both animal models and healthy volunteers. The investigators recently conducted a large phase 2 study of Brensocatib in patients with bronchiectasis designed to test if treatment with Brensocatib could reduce infective exacerbations and reduce neutrophil elastase activity in the lung in bronchiectasis patients. The study met its primary endpoint of time to first exacerbation and key secondary endpoint of the frequency of exacerbations as well as showing marked reductions in neutrophil elastase concentrations in sputum. Due to the need to replace the circulating pool of neutrophils with new neutrophils which are deficient in elastase, Brensocatib does not have its effect immediately, but rather over several days. Elastase concentrations were reduced at the first time point at day 14 in the phase 2 study, with very large reductions observed at the second time point at day 28. In a cohort of 191 hospitalised COVID-19 patients with a completed outcome, the median time from illness onset to discharge was 22·0 days (IQR 18·0-25·0) and the median time to death was 18·5 days (15·0-22·0). Thirty-two patients (17%) required invasive mechanical ventilation and the median time from onset to mechanical ventilation was 14.5 days. The investigators hypothesise that the mechanism of action of Brensocatib to reduce protease activity will be more rapid in COVID-19 patients compared to bronchiectasis due to a more rapid turnover of neutrophils in acute illness. The objective is to test whether by reducing neutrophil protease activity in neutrophils the investigatorscan prevent or reverse the development of ARDS and thereby improve outcomes in individuals with COVID-19 infection.
Interventions
DRUGBrensocatib
Selective, competitive, and reversible inhibitor of DPP1
DRUGPlacebo
Matched placebo
Sponsors
NHS Tayside
Insmed Incorporated
University of Dundee
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
6.1. Inclusion criteria • Male or female * ≥16 years of age * SARS-CoV-2 infection (clinically suspected+ or laboratory confirmed\*). * Admitted to hospital as in-patient less than 96 hours prior to randomisation\^ * Illness of any duration, and at least one of the following: * Radiographic infiltrates by imaging (e.g. chest x-ray, computed tomography (CT) scan) OR * Evidence of rales/crackles on physical examination OR * Peripheral capillary oxygen saturation (SpO2) ≤94% on room air prior to randomization OR * Requiring supplemental oxygen. OR * Lymphocyte count \<1 x 109 cells per litre (L) * Participant (or legally authorized representative) provides written informed consent * Able to take oral medication * Participant (or legally authorised representative) understands and agrees to comply with planned trial procedures. * Laboratory-confirmed: SARS-CoV-2 infection as determined by polymerase chain reaction (PCR), or other commercial or public health assay in any specimen \< 96 hours prior to randomization. * Clinically suspected: in general, SARS-CoV-2 infection should be suspected when a patient presents with (i) typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and (ii) compatible chest X-ray findings (consolidation or ground-glass shadowing); and (iii) alternative causes have been considered unlikely or excluded (e.g. heart failure, influenza). However, the diagnosis remains a clinical one based on the opinion of the managing doctor * Where a patient has been admitted to hospital for a non COVID-19 reason and develops COVID-19 symptoms whilst an in-patient, randomisation may occur up to 96 hours from onset of symptoms.
Exclusion criteria
* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 5 times the upper limit of normal, result within 72 hours of randomization (the result closest to randomization should be used if several results are available). * History of severe liver disease * Stage 4 severe chronic kidney disease or requiring dialysis (i.e. estimated Glomerular Filtration Rate \< 30), result within 72 hours of randomization (the result closest to randomization should be used if several results are available) * Absolute neutrophil count less than 1.0 x 109 cells per L within 72 hours of randomization (the result closest to randomization should be used if several results are available) * Current treatments with potent Cyp3A4 inducers/inhibitors (e.g Itraconazole, Ketoconazole, diltiazem, verapamil, phenytoin or rifampicin) * HIV treatments - current treatment with protease/integrase inhibitors or non-nucleoside reverse transcriptase inhibitors\* * Pregnant or breast feeding. * Anticipated transfer to another hospital which is not a trial site within 24 hours. * Allergy to Brensocatib * Use of any investigational drug within five times of the elimination half-life after the last trial dose or within 30 days, whichever is longer. Co-enrolment with COVID-19 trials is allowed as per co-enrolment agreements and/or individual decision by the Chief Investigator. Women of child-bearing potential must be willing to have pregnancy testing prior to trial entry. \*The Liverpool HIV checker (https://www.hiv-druginteractions.org/checker) should be used to check for any HIV drug interactions. Simvastatin could be used as a surrogate for Brensocatib as it metabolised similarly by CYP 3A4 pathway. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Participant Clinical Status Between Treatment Arms | Up to 29 days | To determine the participant clinical status on a 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitation on activities; 3. Hospitalised, not requiring supplemental oxygen; 4. Hospitalised, requiring supplemental oxygen; 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Mechanical Ventilator Free Days | 1-29 days | Evaluation of the clinical efficacy of Brensocatib relative to standard care: Mechanical ventilation |
| Changes in White Cell Count (x10^9/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Haemoglobin (g/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Platelets (x10^9/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Creatinine (Umol/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Total Bilirubin (Umol/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Alanine Aminotransferase (U/L) Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Changes in Aspartate Aminotransferase U/L Over Time (Hospitalised Participants Only) | Day 29 | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
| Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | 1-29 days | Evaluation of the safety of the intervention through 29 days of follow-up as compared to the control arm |
| Improvement of One Category From Admission Using 7-point Ordinal Scale. | Day 29 | Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death |
| Participant Clinical Status on 7-point Ordinal Scale | Day 15 | Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death |
| Mean Change in the 7-point Ordinal Scale | Baseline to days 3, 5, 8, 11 and 29 | Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death |
| Number of Participants Discharged or to a National Early Warning Score (NEWS) of Equal or Less Than 2 and Maintained for 24 Hours, Whichever Occurs First. | Up to 29 days | Evaluation of the clinical efficacy of Brensocatib relative to standard care: National Early Warning Score (NEWS). NEWS is a system that scores 6 physiological parameters (respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, temperature) to give an aggerate score. Minimum score is 1, maximum score is 20.. Higher scores indicate worsening clinical outcomes. |
| Change From Baseline of National Early Warning Score (NEWS). | Baseline to day 15 | Evaluation of the clinical efficacy of Brensocatib relative to standard care: National Early Warning Score. NEWS is a system that scores 6 physiological parameters (respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, temperature) to give an aggerate score. Minimum score is 1, maximum score is 20.. Higher scores indicate worsening clinical outcomes. |
| Number of Oxygen Therapy Free Days | 1-29 days | Evaluation of the clinical efficacy of Brensocatib relative to standard care: oxygenation |
| Incidence and Duration of New Oxygen Therapy Use During the Trial | 0-29 days | Evaluation of the clinical efficacy of Brensocatib relative to standard care: oxygenation |
| Incidence and Duration of New Mechanical Ventilation Use During the Trial. | 1-29 days | Evaluation of the clinical efficacy of Brensocatib relative to standard care: Mechanical ventilation |
| Duration of Hospitalisation (Days). | Duration between date of admission and discharge assessed up to 29 days. | Evaluation of the clinical efficacy of Brensocatib relative to standard care: hospitalisation |
| 28-day Mortality | Day 1 to 29 | Evaluation of the clinical efficacy of Brensocatib relative to standard care: mortality. Survival analysis was used to compare 28-day mortality between the treatment arms. Participants who did not die were censored on the last study day. Those who withdrew or were loss to follow-up and their day 29 status was unknown were censored at the date of loss to follow-up/withdrawal. Other participants were censored 28 days from randomisation in study time. |
| Cumulative Incidence of Serious Adverse Events (SAEs) | 1-29 days | Evaluation of the safety of the intervention through 29 days of follow-up as compared to the control arm |
| Discontinuation or Temporary Suspension of Treatment | 1-29 days | Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm |
Other
| Measure | Time frame | Description |
|---|---|---|
| Neutrophil Elastase and Heparin Binding Protein Measurement in Blood | Days 1, 8, 15, 29 | Evaluation of the virologic efficacy of Brensocatib by measuring neutrophil elastase and heparin binding protein measurement in blood |
| Blood Neutrophil Elastase Activity | Day 29 | Neutrophil elastase activity was measure as follows: whole blood samples were treated with either 10mg/mL zymosan to stimulate neutrophil degranulation or with hanks' balanced salt solution (HBSS) at 37°C for 30 minutes. Following incubation, samples were centrifuged, and blood plasma frozen at -80°C for analysis. Neutrophil elastase activity was subsequently measured by cleavage of the specific fluorogenic substrate MeOSuc-AAPV-AMC. The stimulated elastase activity was calculated by subtracting the plasma elastase activity following incubation with zymosan stimulation from the elastase activity after incubation with buffer alone. Results presents arbitrary fluorescence intensity units (units/mL) as no reference standard is included in the assay. This outcome was included to assess the inhibition of neutrophil serine proteases by DPP1 treatment. Lower values indicate reduced elastase activity. |
| Neutrophil Extracellular Trap Release | Days 1, 15, 29 | Evaluation of the virologic efficacy of Brensocatib |
| Neutrophil Surface Protein Expression Analysis | Days 1, 15, 29 | Evaluation of the virologic efficacy of Brensocatib by flow cytometry- CD88, CXCR2, CD66b, CD11b, CD63) |
| Neutrophil Phagocytosis of FITC-labelled Bacteria by Flow Cytometry | Days 1, 15, 29 | Evaluation of the virologic efficacy of Brensocatib by flow cytometry |
| Quality of Life Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | Day 29 | To evaluate patient reported outcome measures between the groups using EQ-5D-5L questionnaire. EQ-5D-5L comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and each dimension has 5 levels. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The total EQ-5D-5L score ranges from -0.594 to 1. A higher total score indicates better outcome. |
| Quantitative SARS-CoV-2 Virus in Nasopharyngeal Samples. | Day 15 and day 29 | Evaluation of the virologic efficacy of Brensocatib by assessing presence of SARS-CoV-2 virus in nasopharyngeal samples |
| Percent of Participants With SARS-CoV-2 Detectable in Nasopharyngeal Sample | Day 15 and day 29 | Evaluation of the virologic efficacy of Brensocatib by assessing percent of participants with SARS-CoV-2 detectable in nasopharyngeal sample |
Countries
United Kingdom
Participant flow
Recruitment details
This double-blind, randomized, parallel-group, placebo-controlled trial was conducted at 14 secondary care sites in the United Kingdom Between 05th June 2020 and 28 February 2021
Pre-assignment details
There were two post-randomisation exclusions due to ineligibility in the Brensocatib arm (one was admitted to hospital as an in-patient more than 96 hours prior to randomisation and another was receiving a prohibited medication). These two patients were included in the safety analysis. Four hundred and four participants (190 Brensocatib and 214 placebo) were included in the intention-to-treat analysis.
Participants by arm
| Arm | Count |
|---|---|
| Brensocatib Brensocatib oral tablet, 25mg once per day for 28 days
Brensocatib: Selective, competitive, and reversible inhibitor of DPP1 | 190 |
| Placebo Placebo oral tablet, 25mg once per day for 28 days
Placebo: Matched placebo | 214 |
| Total | 404 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lost to Follow-up | 3 | 3 |
| Overall Study | Protocol Violation | 2 | 0 |
Baseline characteristics
| Characteristic | Total | Placebo | Brensocatib |
|---|---|---|---|
| Age, Continuous | 62.2 years STANDARD_DEVIATION 13.9 | 62.0 years STANDARD_DEVIATION 14.9 | 62.3 years STANDARD_DEVIATION 12.5 |
| Chronic cardiac disease | 71 Participants | 37 Participants | 34 Participants |
| COPD | 51 Participants | 22 Participants | 29 Participants |
| Diabetes without complications | 62 Participants | 33 Participants | 29 Participants |
| Hospitalized, not requiring supplemental oxygen | 92 Participants | 50 Participants | 42 Participants |
| Hospitalized, on non-invasive ventilation or high flow oxygen devices | 44 Participants | 24 Participants | 20 Participants |
| Hospitalized, requiring supplemental oxygen | 268 Participants | 140 Participants | 128 Participants |
| Obesity | 89 Participants | 48 Participants | 41 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 20 Participants | 11 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 3 Participants | 3 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 9 Participants | 4 Participants | 5 Participants |
| Race (NIH/OMB) White | 370 Participants | 195 Participants | 175 Participants |
| Sex: Female, Male Female | 152 Participants | 87 Participants | 65 Participants |
| Sex: Female, Male Male | 252 Participants | 127 Participants | 125 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 29 / 192 | 23 / 214 |
| other Total, other adverse events | 86 / 192 | 99 / 214 |
| serious Total, serious adverse events | 40 / 192 | 35 / 214 |
Outcome results
Primary
Comparison of Participant Clinical Status Between Treatment Arms
To determine the participant clinical status on a 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitation on activities; 3. Hospitalised, not requiring supplemental oxygen; 4. Hospitalised, requiring supplemental oxygen; 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death.
Time frame: Up to 29 days
Population: Intention to treat
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Not hospitalized, no limitations on activities | 28 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Not hospitalized, limitations on activities | 112 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, not requiring supplemental oxygen | 7 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, requiring supplemental oxygen | 6 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, on non-invasive ventilation or high flow oxygen devices | 0 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, on invasive mechanical ventilation or ECMO | 5 participants |
| Brensocatib | Comparison of Participant Clinical Status Between Treatment Arms | Death | 29 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, requiring supplemental oxygen | 1 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Not hospitalized, no limitations on activities | 40 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, on invasive mechanical ventilation or ECMO | 6 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Not hospitalized, limitations on activities | 129 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, on non-invasive ventilation or high flow oxygen devices | 1 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Hospitalized, not requiring supplemental oxygen | 11 participants |
| Placebo | Comparison of Participant Clinical Status Between Treatment Arms | Death | 23 participants |
p-value: 0.00895% CI: [0.57, 0.92]Odds ratio Ordinal Logistic Regression
Secondary
28-day Mortality
Evaluation of the clinical efficacy of Brensocatib relative to standard care: mortality. Survival analysis was used to compare 28-day mortality between the treatment arms. Participants who did not die were censored on the last study day. Those who withdrew or were loss to follow-up and their day 29 status was unknown were censored at the date of loss to follow-up/withdrawal. Other participants were censored 28 days from randomisation in study time.
Time frame: Day 1 to 29
Population: ITT
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brensocatib | 28-day Mortality | 29 Participants |
| Placebo | 28-day Mortality | 23 Participants |
95% CI: [1.06, 1.88]
Secondary
Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications
Evaluation of the safety of the intervention through 29 days of follow-up as compared to the control arm
Time frame: 1-29 days
Population: Safety
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Brensocatib | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Hyperkeratosis | 0 Participants |
| Brensocatib | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Dental complications | 0 Participants |
| Brensocatib | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Secondary infections | 6 Participants |
| Placebo | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Hyperkeratosis | 0 Participants |
| Placebo | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Dental complications | 1 Participants |
| Placebo | Adverse Events of Special Interest- Hyperkeratosis, Infections and Dental Complications | Secondary infections | 7 Participants |
Secondary
Change From Baseline of National Early Warning Score (NEWS).
Evaluation of the clinical efficacy of Brensocatib relative to standard care: National Early Warning Score. NEWS is a system that scores 6 physiological parameters (respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, temperature) to give an aggerate score. Minimum score is 1, maximum score is 20.. Higher scores indicate worsening clinical outcomes.
Time frame: Baseline to day 15
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 1 | 22 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -4 | 1 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 2 | 36 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -8 | 0 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 3 | 28 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -3 | 4 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 4 | 21 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -6 | 0 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 5 | 10 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -2 | 1 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 6 | 11 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -9 | 2 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 7 | 3 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -1 | 3 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 8 | 1 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -5 | 1 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 9 | 0 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 0 | 15 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | 10 | 0 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -7 | 1 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | missing | 29 Participants |
| Brensocatib | Change From Baseline of National Early Warning Score (NEWS). | -11 | 1 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | missing | 26 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -11 | 0 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -9 | 0 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -8 | 1 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -7 | 0 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -6 | 2 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -5 | 0 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -4 | 3 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -3 | 1 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -2 | 1 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | -1 | 3 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 0 | 24 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 1 | 24 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 2 | 34 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 3 | 36 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 4 | 28 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 5 | 14 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 6 | 6 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 7 | 4 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 8 | 4 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 9 | 2 Participants |
| Placebo | Change From Baseline of National Early Warning Score (NEWS). | 10 | 1 Participants |
Secondary
Changes in Alanine Aminotransferase (U/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Alanine Aminotransferase (U/L) Over Time (Hospitalised Participants Only) | 62.8 U/L | Standard Deviation 43.2 |
| Placebo | Changes in Alanine Aminotransferase (U/L) Over Time (Hospitalised Participants Only) | 52.3 U/L | Standard Deviation 92.8 |
Secondary
Changes in Aspartate Aminotransferase U/L Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Aspartate Aminotransferase U/L Over Time (Hospitalised Participants Only) | 22 U/L | Standard Deviation 11.4 |
| Placebo | Changes in Aspartate Aminotransferase U/L Over Time (Hospitalised Participants Only) | 28.8 U/L | Standard Deviation 14.9 |
Secondary
Changes in Creatinine (Umol/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Hospitalised patients only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Creatinine (Umol/L) Over Time (Hospitalised Participants Only) | 84.9 umol/L | Standard Deviation 39 |
| Placebo | Changes in Creatinine (Umol/L) Over Time (Hospitalised Participants Only) | 84.1 umol/L | Standard Deviation 52 |
Secondary
Changes in Haemoglobin (g/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Hospitalised participants only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Haemoglobin (g/L) Over Time (Hospitalised Participants Only) | 195.4 g/l | Standard Deviation 264 |
| Placebo | Changes in Haemoglobin (g/L) Over Time (Hospitalised Participants Only) | 105.5 g/l | Standard Deviation 21.7 |
Secondary
Changes in Platelets (x10^9/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Platelets (x10^9/L) Over Time (Hospitalised Participants Only) | 270 10^9cells/L | Standard Deviation 94.3 |
| Placebo | Changes in Platelets (x10^9/L) Over Time (Hospitalised Participants Only) | 269 10^9cells/L | Standard Deviation 117 |
Secondary
Changes in Total Bilirubin (Umol/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Safety
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in Total Bilirubin (Umol/L) Over Time (Hospitalised Participants Only) | 8.4 umol/L | Standard Deviation 3.9 |
| Placebo | Changes in Total Bilirubin (Umol/L) Over Time (Hospitalised Participants Only) | 9.3 umol/L | Standard Deviation 9.8 |
Secondary
Changes in White Cell Count (x10^9/L) Over Time (Hospitalised Participants Only)
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: Day 29
Population: Hospitalised participants only
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Changes in White Cell Count (x10^9/L) Over Time (Hospitalised Participants Only) | 8.9 10^9cells/L | Standard Deviation 4.7 |
| Placebo | Changes in White Cell Count (x10^9/L) Over Time (Hospitalised Participants Only) | 8.5 10^9cells/L | Standard Deviation 3.1 |
Secondary
Cumulative Incidence of Serious Adverse Events (SAEs)
Evaluation of the safety of the intervention through 29 days of follow-up as compared to the control arm
Time frame: 1-29 days
Population: There were two post-randomisation exclusions due to ineligibility in the brensocatib group (one patient was admitted to hospital as an inpatient more than 96 h before randomisation and another was receiving a prohibited medication). These 2 excluded patients were included with the ITT population in the safety analysis
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brensocatib | Cumulative Incidence of Serious Adverse Events (SAEs) | 40 Participants |
| Placebo | Cumulative Incidence of Serious Adverse Events (SAEs) | 35 Participants |
Secondary
Discontinuation or Temporary Suspension of Treatment
Evaluation of the safety of the intervention through 28 days of follow-up as compared to the control arm
Time frame: 1-29 days
Population: Safety
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brensocatib | Discontinuation or Temporary Suspension of Treatment | 13 Participants |
| Placebo | Discontinuation or Temporary Suspension of Treatment | 12 Participants |
Secondary
Duration of Hospitalisation (Days).
Evaluation of the clinical efficacy of Brensocatib relative to standard care: hospitalisation
Time frame: Duration between date of admission and discharge assessed up to 29 days.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Duration of Hospitalisation (Days). | 8.4 days | Standard Deviation 8.3 |
| Placebo | Duration of Hospitalisation (Days). | 8.2 days | Standard Deviation 8.3 |
95% CI: [0.92, 1.15]
Secondary
Improvement of One Category From Admission Using 7-point Ordinal Scale.
Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death
Time frame: Day 29
Population: ITT. Days to improvement was derived as~1. days from randomization to date of first follow-up day where there was an improvement in CSTAT~2. those who died before improvement were censored at date of death.~3. those who withdrew or were loss to follow-up before improvement, if their day 29 status was unknown, they were censored at the date of loss to follow-up/withdrawal~4. other participants were censored at day 29 from randomisation in study time if there were no improvement.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brensocatib | Improvement of One Category From Admission Using 7-point Ordinal Scale. | 159 Participants |
| Placebo | Improvement of One Category From Admission Using 7-point Ordinal Scale. | 186 Participants |
p-value: 0.05895% CI: [0.76, 1]Regression, Cox
Secondary
Incidence and Duration of New Mechanical Ventilation Use During the Trial.
Evaluation of the clinical efficacy of Brensocatib relative to standard care: Mechanical ventilation
Time frame: 1-29 days
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brensocatib | Incidence and Duration of New Mechanical Ventilation Use During the Trial. | 0 days |
| Placebo | Incidence and Duration of New Mechanical Ventilation Use During the Trial. | 0 days |
95% CI: [1.09, 2.58]
Secondary
Incidence and Duration of New Oxygen Therapy Use During the Trial
Evaluation of the clinical efficacy of Brensocatib relative to standard care: oxygenation
Time frame: 0-29 days
Population: For the duration of new oxygen use analysis, only participants who were hospitalised but not requiring supplemental oxygen (CSTAT = 3) at baseline were included
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brensocatib | Incidence and Duration of New Oxygen Therapy Use During the Trial | 0 days |
| Placebo | Incidence and Duration of New Oxygen Therapy Use During the Trial | 0 days |
95% CI: [0.73, 1.74]
Secondary
Mean Change in the 7-point Ordinal Scale
Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death
Time frame: Baseline to days 3, 5, 8, 11 and 29
Population: ITT
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 15 | 1.0 Units on WHO scale | Standard Deviation 1.8 |
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 29 | 1.0 Units on WHO scale | Standard Deviation 2 |
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 11 | 0.9 Units on WHO scale | Standard Deviation 1.6 |
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 8 | 0.7 Units on WHO scale | Standard Deviation 1.5 |
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 5 | 0.5 Units on WHO scale | Standard Deviation 1.1 |
| Brensocatib | Mean Change in the 7-point Ordinal Scale | Baseline to day 3 | 0.2 Units on WHO scale | Standard Deviation 0.8 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 5 | 0.5 Units on WHO scale | Standard Deviation 1.1 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 15 | 1.2 Units on WHO scale | Standard Deviation 1.6 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 8 | 0.9 Units on WHO scale | Standard Deviation 1 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 29 | 1.3 Units on WHO scale | Standard Deviation 2 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 3 | 0.2 Units on WHO scale | Standard Deviation 0.9 |
| Placebo | Mean Change in the 7-point Ordinal Scale | Baseline to day 11 | 1.1 Units on WHO scale | Standard Deviation 1.5 |
Secondary
Number of Mechanical Ventilator Free Days
Evaluation of the clinical efficacy of Brensocatib relative to standard care: Mechanical ventilation
Time frame: 1-29 days
Population: ITT
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brensocatib | Number of Mechanical Ventilator Free Days | 28 days |
| Placebo | Number of Mechanical Ventilator Free Days | 28 days |
95% CI: [0.69, 1.04]
Secondary
Number of Oxygen Therapy Free Days
Evaluation of the clinical efficacy of Brensocatib relative to standard care: oxygenation
Time frame: 1-29 days
Population: ITT.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Brensocatib | Number of Oxygen Therapy Free Days | 24 days |
| Placebo | Number of Oxygen Therapy Free Days | 24.5 days |
95% CI: [0.87, 0.99]
Secondary
Number of Participants Discharged or to a National Early Warning Score (NEWS) of Equal or Less Than 2 and Maintained for 24 Hours, Whichever Occurs First.
Evaluation of the clinical efficacy of Brensocatib relative to standard care: National Early Warning Score (NEWS). NEWS is a system that scores 6 physiological parameters (respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new-onset confusion, temperature) to give an aggerate score. Minimum score is 1, maximum score is 20.. Higher scores indicate worsening clinical outcomes.
Time frame: Up to 29 days
Population: ITT. Those who died before being discharged or having a NEWS of ≤ 2 were censored at date of death. For those who withdrew or were loss to follow-up before being discharged or having a NEWS of ≤ 2, if their day 29 status was unknown, they were censored at the date of loss to follow-up/withdrawal. Other participants were censored at day 29 or 28 days from randomisation in study time if they were still in hospital and never had a NEWS of ≤ 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Brensocatib | Number of Participants Discharged or to a National Early Warning Score (NEWS) of Equal or Less Than 2 and Maintained for 24 Hours, Whichever Occurs First. | 172 Participants |
| Placebo | Number of Participants Discharged or to a National Early Warning Score (NEWS) of Equal or Less Than 2 and Maintained for 24 Hours, Whichever Occurs First. | 195 Participants |
95% CI: [0.84, 1.13]
Secondary
Participant Clinical Status on 7-point Ordinal Scale
Evaluation of the clinical efficacy of Brensocatib relative to standard care: 7-point ordinal scale, minimum value 1, maximum value 7. Higher values indicate a worse outcome: 1. Not hospitalised, no limitations on activities 2. Not hospitalised, limitations on activities 3. Hospitalised, not requiring supplemental oxygen 4. Hospitalised, requiring supplemental oxygen 5. Hospitalised, on non-invasive ventilation or high flow oxygen devices 6. Hospitalised, on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO) 7. Death
Time frame: Day 15
Population: ITT
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Not hospitalised, no limitations on activities | 22 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Not hospitalised, limitations on activities | 103 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, not requiring supplemental oxygen | 12 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, requiring supplemental oxygen | 16 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, on non-invasive ventilation or high flow oxygen devices | 3 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, on invasive mechanical ventilation or ECMO | 9 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Death | 20 Participants |
| Brensocatib | Participant Clinical Status on 7-point Ordinal Scale | Missing | 5 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Missing | 3 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Not hospitalised, no limitations on activities | 26 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, on non-invasive ventilation or high flow oxygen devices | 5 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Not hospitalised, limitations on activities | 124 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Death | 18 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, not requiring supplemental oxygen | 19 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, on invasive mechanical ventilation or ECMO | 6 Participants |
| Placebo | Participant Clinical Status on 7-point Ordinal Scale | Hospitalised, requiring supplemental oxygen | 13 Participants |
Other Pre-specified
Blood Neutrophil Elastase Activity
Neutrophil elastase activity was measure as follows: whole blood samples were treated with either 10mg/mL zymosan to stimulate neutrophil degranulation or with hanks' balanced salt solution (HBSS) at 37°C for 30 minutes. Following incubation, samples were centrifuged, and blood plasma frozen at -80°C for analysis. Neutrophil elastase activity was subsequently measured by cleavage of the specific fluorogenic substrate MeOSuc-AAPV-AMC. The stimulated elastase activity was calculated by subtracting the plasma elastase activity following incubation with zymosan stimulation from the elastase activity after incubation with buffer alone. Results presents arbitrary fluorescence intensity units (units/mL) as no reference standard is included in the assay. This outcome was included to assess the inhibition of neutrophil serine proteases by DPP1 treatment. Lower values indicate reduced elastase activity.
Time frame: Day 29
Population: Substudy
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Blood Neutrophil Elastase Activity | 103 Units/ml | Standard Deviation 65 |
| Placebo | Blood Neutrophil Elastase Activity | 166 Units/ml | Standard Deviation 97 |
95% CI: [-102, -31]
Other Pre-specified
Neutrophil Elastase and Heparin Binding Protein Measurement in Blood
Evaluation of the virologic efficacy of Brensocatib by measuring neutrophil elastase and heparin binding protein measurement in blood
Time frame: Days 1, 8, 15, 29
Other Pre-specified
Neutrophil Extracellular Trap Release
Evaluation of the virologic efficacy of Brensocatib
Time frame: Days 1, 15, 29
Other Pre-specified
Neutrophil Phagocytosis of FITC-labelled Bacteria by Flow Cytometry
Evaluation of the virologic efficacy of Brensocatib by flow cytometry
Time frame: Days 1, 15, 29
Other Pre-specified
Neutrophil Surface Protein Expression Analysis
Evaluation of the virologic efficacy of Brensocatib by flow cytometry- CD88, CXCR2, CD66b, CD11b, CD63)
Time frame: Days 1, 15, 29
Other Pre-specified
Percent of Participants With SARS-CoV-2 Detectable in Nasopharyngeal Sample
Evaluation of the virologic efficacy of Brensocatib by assessing percent of participants with SARS-CoV-2 detectable in nasopharyngeal sample
Time frame: Day 15 and day 29
Other Pre-specified
Quality of Life Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)
To evaluate patient reported outcome measures between the groups using EQ-5D-5L questionnaire. EQ-5D-5L comprises of five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and each dimension has 5 levels. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The total EQ-5D-5L score ranges from -0.594 to 1. A higher total score indicates better outcome.
Time frame: Day 29
Population: ITT
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Brensocatib | Quality of Life Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | 0.67 units on a scale | Standard Deviation 0.29 |
| Placebo | Quality of Life Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) | 0.67 units on a scale | Standard Deviation 0.25 |
95% CI: [-0.06, 0.066]
Other Pre-specified
Quantitative SARS-CoV-2 Virus in Nasopharyngeal Samples.
Evaluation of the virologic efficacy of Brensocatib by assessing presence of SARS-CoV-2 virus in nasopharyngeal samples
Time frame: Day 15 and day 29